Immune checkpoint inhibitors have been successful across several tumor types; however, their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where <10% of patients show long-term responses. To understand the molecular determinants of immunotherapeutic response in GBM, we longitudinally profiled 66 patients, including 17 longterm responders, during standard therapy and after treatment with PD-1 inhibitors (nivolumab or pembrolizumab). Genomic and transcriptomic analysis revealed a significant enrichment of PTEN mutations associated with immunosuppressive expression signatures in non-responders, and an enrichment of MAPK pathway alterations (PTPN11, BRAF) in responders. Responsive tumors were also associated with branched patterns of evolution from the elimination of neoepitopes as well as with differences in T cell clonal diversity and tumor microenvironment profiles. Our study shows that clinical response to anti-PD-1 immunotherapy in GBM is associated with specific molecular alterations, immune expression signatures, and immune infiltration that reflect the tumor's clonal evolution during treatment.
Immune checkpoint inhibitors have been successful across several tumor types; however, their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where <10% of patients show long-term responses. To understand the molecular determinants of immunotherapeutic response in GBM, we longitudinally profiled 66 patients, including 17 longterm responders, during standard therapy and after treatment with PD-1 inhibitors (nivolumab or pembrolizumab). Genomic and transcriptomic analysis revealed a significant enrichment of PTEN mutations associated with immunosuppressive expression signatures in non-responders, and an enrichment of MAPK pathway alterations (PTPN11, BRAF) in responders. Responsive tumors were also associated with branched patterns of evolution from the elimination of neoepitopes as well as with differences in T cell clonal diversity and tumor microenvironment profiles. Our study shows that clinical response to anti-PD-1 immunotherapy in GBM is associated with specific molecular alterations, immune expression signatures, and immune infiltration that reflect the tumor's clonal evolution during treatment.
Glioblastoma is the most common primary brain malignancy in adults. The current standard of care for newly diagnosed glioblastoma has limited efficacy, with a median overall survival of approximately 16-20 months 1 . There is still no effective treatment for progressive or relapsed GBM, which invariably occurs in most patients. In the last decade, immunotherapy with checkpoint inhibitors has shown remarkable success in treating a variety of tumors, including advanced melanoma 2 , non-small-cell lung cancer 3 , and Hodgkin's lymphoma 4 , among others. There has been considerable interest in utilizing immunotherapy in GBM, but a recent clinical trial of programed cell death 1 (PD-1) immune checkpoint inhibitors in recurrent glioblastoma showed that only a small subset of patients (8%) demonstrated objective responses 5 . The mechanistic basis for the variation in response patterns remains to be explained.
Improved response to anti-PD-1 therapy has been found to be associated with higher mutational burdens in tumors across multiple cancer types 6, 7 as well as with levels of T cell infiltration in the tumor microenvironment 8 . However, compared with melanomas or non-small-cell lung cancer, GBM harbors a lower burden of somatic mutations 9 and a more immunosuppressive tumor microenvironment. One mechanism of immunosuppression is T cell exhaustion and apoptosis via PD-1 ligands (PD-L1/2) expressed by tumor cells: on binding PD-1 on the surface of cytotoxic T cells, the T cells become incapable of eliciting effective anti-tumor responses. PD-1 inhibitor therapy impairs this immune checkpoint and enhances the anti-tumor immune response 8 . Given the variable and unpredictable response of patients with GBM to PD-1 inhibitor therapies, we have extensively profiled 66 patients across a variety of timepoints, collecting DNA, RNA, tissue imaging, and clinical data (Fig. 1a) . We sought to evaluate the genomic and stromal features associated with clinical outcomes and to gain insight into the underlying mechanisms of immunotherapy response.
We compiled a retrospective series of 66 adult patients with GBM who were treated with PD-1 inhibitors (pembrolizumab or nivolumab) on recurrence. Baseline patient characteristics and available data modalities of our cohort can be found in Supplementary  Table 1 and Extended Data Fig. 1a .
Patients were classified as responders if they met at least one of the following two criteria:
(1) Tissue sampled during surgery after PD-1 inhibitor therapy grossly showed only an inflammatory response and very few to no tumor cells (as associated with pseudo-progression). (2) Tumor volumes, as seen from magnetic resonance imaging (MRI), were either stable or shrinking continually over at least 6 months.
In Fig. 1b , we show brain MRIs of two patients treated with nivolumab with their corresponding relative timelines. Patient NU 7 showed progression after 2 months of nivolumab as measured by the RANO criteria 10 . Meanwhile, patient NU 11 showed stable disease without progression after 17 months.
Demographic and clinical characteristics, including response pattern, age at treatment initiation, gender, and choice of PD-1
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inhibitor, were evaluated in a univariate survival analysis (Fig. 1c) . Since criterion 2 of our definition of response contains a temporal component, to avoid potential confounding, we excluded from this analysis patients whose survival was less than 6 months. Response to the PD-1 inhibitor was found to be most significantly associated with overall survival as measured from the initiation of immunotherapy: patients who showed a responsive pattern to anti-PD-1 immunotherapy had a median survival of 14.3 months compared with the 10.1 months of non-responsive patients (P = 0.0081, logrank test) (Fig. 1d) . Without excluding patients, this effect was even stronger: responders had a median survival of 15.5 months, whereas it was 5.7 months for non-responders (P = 2.2 × 10 , log-rank test) (Extended Data Fig. 1b,d) . Similarly, survival as measured from initial diagnosis was also increased in responders (P = 1.6 × −3
, logrank test; Extended Data Fig. 1c ). However, there was no significant difference in the time span between initial diagnosis and the start of anti-PD-1 treatment between the two groups (P = 0.96, Wilcoxon rank-sum test).
We analyzed 58 whole exomes and 38 transcriptomes from longitudinal tumor-matched blood normal samples for 17 patients, with nivolumab, one of whom showed disease progression following 2 months of treatment (left, NU 7) while the other showed stable disease without progression after 17 months of treatment (right, NU 11). c, Univariate survival analysis revealed that only response to anti-PD-1 therapy is significantly correlated with overall survival of the patients (n = 25); P value, two-sided log-rank test. d, Kaplan-Meier curve comparing overall survival of patients who responded to anti-PD-1 therapy (n = 13) with those that did not respond (n = 12); P value, two-sided log-rank test.
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and also incorporated the results from a cancer gene panel of 39 patients (Fig. 2a) .
We identified a median of 47 non-synonymous somatic mutations in the 33 tumors, with a range from 14 to 83, typical for GBM 11 (Supplementary Table 2 ). Contrary to previous observations in other tumor types 6, 7, 12 , we did not find more non-synonymous single nucleotide variants (nsSNVs) in the responsive compared with the non-responsive baseline tumors (Extended Data Fig. 2 ). In fact, we observed a non-significant trend in the opposite direction; on the basis of the pre-treatment samples from the first surgery for each patient, non-responders had a median nsSNV count of 40, whereas it was 26 for responders (P = 0.11, Wilcoxon ranksum test). A statistically non-significant trend was also observed between response and aneuploidy (P = 0.88, t-test; Extended Data Fig. 2) 
13
. Similarly, human leukocyte antigen class I (HLA-I) neoepitope load predictions yielded similar patterns for the two groups (median of 45 in non-responders and 35 in responders, P = 0.41, Wilcoxon rank-sum test). Although a recent study has shown that zygosity at HLA-I genes influences survival of advanced melanoma and non-small-cell lung cancer patients treated with immunotherapies 14 , we did not find any significant association between HLA zygosity with immunotherapy response or survival. Additionally, there was no significant difference of tumor purity between these two groups (median of 0.41 in non-responders and 0.38 in responders, P = 0.19, Wilcoxon rank-sum test).
We then sought to identify mutations (nsSNVs and indels) that were significantly enriched in either responsive or non-responsive tumors. In total, we identified 11 IDH1 R132G/H mutated tumors, of which four were found in responders and seven in non-responders. Focusing on the remaining 45 IDH1 wild type tumors, we found 23 PTEN mutations among the 32 non-responders, but only three mutations among the 13 responders (Fig. 2b,c) . Within the cohort, PTEN was significantly more frequently mutated in the nonresponsive tumors than in the responsive ones (Fisher P = 0.0063, odds ratio = 8.5, false discovery rate (FDR)-corrected P < 0.05; Fig. 2b, right) . Considering that the background PTEN mutation rate is around 33% (154 of 458 tumors in IDH1 wild type glioblastomas from The Cancer Genome Atlas (TCGA) 15 ), PTEN mutations were also more enriched in non-responders than expected (Fisher P = 0.0018, odds ratio = 3.3, FDR-corrected P < 0.05; Fig. 2b , left; see Methods).
Notably, existing studies in melanoma have shown that PTEN loss in tumor cells increases the expression of immunosuppressive cytokines, resulting in decreased T cell infiltration in tumors and inhibited autophagy, which decreases T cell-mediated cell death 16 . Meanwhile, a study in glioblastoma has shown that tumor-specific T cells lysed PTEN wild type glioma cells more efficiently than those expressing mutant PTEN 17 . By utilizing single-sample geneset enrichment analysis (ssGSEA) to calculate the enrichment score of the PI3K-AKT pathway for each tumor in our cohort, we also observed significantly higher PI3K-AKT pathway activity among PTEN mutant non-responsive tumors (t-test P = 0.049; Extended Data Fig. 3a) . However, we did not find any difference in CD274 (which encodes PD-L1) RNA expression between responsive and non-responsive tumors (t-test P = 0.374; Extended Data Fig. 3b ).
We also found four mutations in the MAPK pathway components (including BRAF and PTPN11) among the 13 responders, and only one among the 32 non-responders (Fig. 2b) . Considering the rarity of MAPK pathway mutations among IDH1 wild-type glioblastoma (mutation rate 7.8%, 36 of 458 tumors from TCGA), MAPK pathway genes were significantly more frequently mutated in the responsive tumors than expected (Fisher P = 0.018, odds ratio = 5.1, FDR-corrected P < 0.05). Similarly, MAPK pathway mutations are also significantly enriched in responders within our cohort (Fisher P = 0.019, odds ratio = 12.8, FDR-corrected P < 0.05). Given the high prevalence of BRAF mutations in melanoma and the dramatic success of immunotherapy in treating advanced melanoma, this finding may have relevant implications for the MAP kinase pathway and immune response 18 . Concordantly, the MAPK pathway was recently implicated in the modulation of T cell recognition of melanoma cells in a genome-wide CRISPR screen analysis 19 . Recent studies in cancer immuno-editing have shown that the immune system selects for tumor variants with reduced immunogenicity, a phenomenon that could contribute to the immune-evasive features of gliomas 20 . The pattern of initial response and later relapse among the responders in our cohort led us to investigate the evolution of tumors undergoing anti-PD-1 immunotherapy. The number of mutations exclusive to, or in common with, each sample was used to construct evolutionary trees for five patients (two nonresponders and three responders) for whom we had both pre-and post-immunotherapy tumor samples (Fig. 2d) .
We found that the tumors from non-responders and responders exhibited different patterns of evolution. The higher fraction of mutations exclusive to post-immunotherapy tumors, compared with the pre-anti-PD-1 treatment case, in the two nonresponders (patients 20 and 53) suggests that they followed the classical linear model of tumor evolution. In contrast, the tumors from two responders (patients 55 and 71) were more similar to the branched model, with clonal alterations in the pre-anti-PD-1 dominant clone not present after therapy, suggesting that specific alterations and evolutionary patterns are associated with treatment ( Fig. 2e ). In the case of patient 55, we found three missense mutations (MYPN R409H, UBQLN3 R159W, CYP27B1 G194E) that were present before anti-PD-1 therapy (recurrent 1), but not after (recurrent 2). Interestingly, one of these mutations (CYP27B1 G194E) is highly expressed (reads per kilobase per million mapped reads (RPKM) > 5) and predicted to result in immunogenic neoantigens. Similarly, for two other responders (patients 71 and 101), we found a missense mutation (FNIP1 T409M and TCF12 A605S, respectively) missing after immunotherapy, which is also highly expressed (RPKM > 5) and predicted to generate a neoantigen (Fig. 2f) .
We also tracked the evolution of lymphocytes within the tumor by identifying T cell antigen receptor (TCR) and immunoglobulin RNA sequences. Across seven patients, we assessed the total number of relevant reads, and the clonal diversity via Shannon entropy, an information theory measure of randomness (Extended Data  Fig. 4 ). We found that non-responders had a greater increase in clonal diversity among T cells compared with responders ( Fig. 3a ; P = 0.024, exact Mann-Whitney U test). Likewise, the same effect was seen in the clonality of immunoglobulin reads, suggesting a similar response in B cells (Extended Data Fig. 5 ; P = 0.048, exact Mann-Whitney U test).
Expression subtyping into proneural, mesenchymal, and classical subtypes 21 did not result in any association with response (Extended Data Fig. 6 ). From a differential enrichment analysis across a total of 9,292 gene sets from MSigDB, we observed that before PD-1 inhibitor treatment, gene sets related to regulatory T (T reg ) cells were enriched among the top-ranked gene sets (P = 0.037; Fig. 3b) . Additionally, enrichment analysis showed that genes upregulated in T reg cells were significantly more active in non-responsive tumors (Extended Data  Fig. 7 ). FOXP3-expressing T reg cells, which suppress aberrant immune response against self-antigens, have been shown to be negatively associated with clinical response to adaptive immunotherapy in human cancers 22 . Interestingly, following immunotherapy, gene sets related to immunosuppression were more active in responsive tumors, including FOXP3 and STAT3 signatures, as well as an immune evasion signature previously reported in renal cell carcinoma 23 ( Fig. 3b) . Immunohistochemistry imaging of five tumors after anti-PD-1 treatment (two responders and three non-responders) did not identify CD4 +
FOXP3
+ T reg cells, suggesting that the aforementioned FOXP3 expression signature originated from another cell type. To investigate the origin of this immune signature, we , t-test; Fig. 3c and Extended Data Fig. 9 ).
The observation that these immune signatures are upregulated in non-responsive tumors suggests that PTEN may play a role in Pre/Post   IDH1  PTEN  PIK3CA  MTOR  BRAF  PTPN11  NF1  KRAS  TP53  ATRX  CIC   1p/19q co-deletion   CDKN2A   CDKN2B   MDM2   MDM4   EGFR   CDK4   CDK6   PDGFRA   PTEN   RB1   TP53   FGFR3-TACC3  FGFR3-TACC1  EGFR-SEPT14   FUS   CNV   MUT   13_1  13_2  13_3  21_1  21_2  21_3  20_1  20_3  53_1  53_2  53_3  53_4  46_1  46_2  69_1  69_2  56_1  56_2  108  4407  106  109  110  4274  4391  5178  4215  4293  4317  4497  NU2  NU15  NU21  NU9  NU17  NU10  NU18  NU19  CU4  CU5  CU6  CU7  CU8  CU11  CU13  CU14  CU15  CU9  CU10  CU12  CU16  24_1  24_2  24_3  25_1  101_1  101_2  101_3  100_1  102_1  3_1  3_2  71_1  71_2  103_1  103_2  55_1  55_2  55_3  104_1  104_2  107  105  4358  NU22  NU11  CU1  CU2 . Consistent with a previous report 27 , correlation analysis revealed that PTEN mutations are significantly associated with higher levels of macrophages, microglia, and neutrophils in the tumor microenvironment (P < 0.05, Wilcoxon rank-sum test, FDR-corrected P < 0.1; Fig. 3d ). As the predominant immune cells infiltrating gliomas, tumor-associated macrophages have been shown to release a wide array of growth factors and cytokines that can facilitate tumor proliferation, survival, and migration 28 . Next, we investigated whether PTEN mutations were associated with the structure of the tumor microenvironment, which 
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we explored with quantitative multiplex immunofluorescence (qmIF) 29, 30 . We stained and analyzed formalin-fixed paraffinembedded (FFPE) specimens from 17 patients with matched pre-and post-anti-PD-1 treatment samples (7 non-responders, 10 responders; Fig. 4a ). We found that PTEN-mutated tumors tended to have higher overall levels of CD68 + macrophage infiltration, although the difference did not reach statistical significance. Given that macrophages have heterogeneous roles, upon further categorization we observed in PTEN-mutated tumors a significantly higher density of CD68 +
HLA-DR
− macrophages (P = 0.011, Wilcoxon rank-sum test; Fig. 4b ), a subpopulation that indicates poor survival in melanoma 29 . Finally, after immunotherapy, the density of CD3 + T cells in PTEN wild-type samples significantly increased compared with pre-treatment samples (P = 0.0095, Wilcoxon rank-sum test; Fig. 4b ), while the PTEN-mutated samples did not show this change. The same pattern was also observed in both CD3
+ CD8 − (P = 0.0095, Wilcoxon rank-sum test; Fig. 4b ) and CD3 + CD8 + T cells (P = 0.038, Wilcoxon rank-sum test; Fig. 4b) .
To assesses the degree of clustering between cell types, we applied a technique from spatial statistics, the pair correlation function. We found that before immunotherapy, tumor cells clustered more strongly with each other in PTEN-mutated cases compared with PTEN wild type (P = 2.4 × 10 , Wilcoxon rank-sum test; Fig. 4c ). Furthermore, in PTEN wild-type cases, macrophages became more strongly clustered with each other following treatment (P = 0.0012, Wilcoxon rank-sum test ; Fig. 4c) ; however, this effect was reversed in PTEN mutants (P = 0.032).
In summary, we have confirmed that GBM patients who were responsive to anti-PD-1 immunotherapy (as evaluated through radiology and pathology) had significantly better overall survival after treatment. In our cohort, tumors from non-responders were significantly enriched for PTEN mutations; furthermore, RNA-seq 
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analysis indicated that these PTEN mutations may induce a distinct immunosuppressive microenvironment. Single-cell RNA profiling revealed that the source of this signature originates not from T reg cells, but rather from tumor cells overexpressing CD44, a marker associated with cellular mobility and GBM aggressiveness 31 . Immunohistochemistry analysis confirmed the lack of increase of T cell infiltration in PTEN mutant tumors, concurring with transcriptomic signatures seen in pretreated cases from TCGA. We also identified differences in spatial structure of the tumor microenvironment that were associated with PTEN status; the increased clustering of tumor cells in PTEN mutants may impede immune infiltration. Similar results were observed in melanoma 16 and in uterine leiomyosarcoma 32 , where PTEN loss was associated with reduced immune infiltration and resistance to anti-PD-1 therapy. Furthermore, the AKT-mTOR pathway downstream of PTEN has been implicated in both PD-L1 expression 33 and immune evasion in cancers 34 . These in turn may determine the response pattern of patients with GBM to anti-PD-1 immunotherapy.
There is good evidence in the literature that alterations in the MAPK signaling pathway are implicated in the development of an unfavorable cancer immune phenotype 35 . However, preclinical evidence suggests that MAPK pathway inhibition can dramatically increase the efficacy of immunotherapy 36 . The observation in our cohort that BRAF/PTPN11 mutations are enriched in tumors responsive to anti-PD-1 therapy supports the rationale for combining checkpoint inhibitors with MAPK-targeted therapy in multiple cancers 35, 37 . Furthermore, these genomic phenomena may be interconnected, as a study in prostate cancer has proposed a PTEN-PTPN11 axis that is responsible for immunosuppression 38 . Another finding in our study is the distinct evolutionary patterns of responding and non-responding tumors under immunotherapy. Although we did not find higher somatic mutation and neoepitope loads in responding tumors, our analysis of their evolution provides strong evidence that the immune system plays an important role in the negative selection of clones containing immunogenic neoepitopes and thus promotes tumors in escaping immune surveillance. This also confirms previous observations from gastrointestinal cancers where low mutational loads did not preclude tumor infiltration by mutation-reactive, class I-and class II-restricted T cells 39 . Additionally, non-responders were found to have a greater increase in T cell diversity following immunotherapy, suggesting that there was a failure of selective recruitment of lymphocytes into the tumor microenvironment. Supporting the role of tumor evolution in shaping the microenvironment, gene sets associated with immunosuppression were more active in non-responders before immunotherapy, but were more active in responders following treatment. These findings are consistent with the notion that tumors of non-responders possessed primary resistance to immunotherapy, whereas responders demonstrate a gradual acquisition of resistance following successful selection pressure 40 .
In conclusion, our study identified multiple genomic features related to response to anti-PD-1 therapy in patients with GBM and depicted distinct evolutionary patterns of GBM under immunotherapy. While overall PD-1 inhibitors do not provide a survival benefit for patients with GBM, our study showed that a sub-group of patients might benefit from this therapy, suggesting a molecular, personalized approach for refining patient selection for immunotherapy. Although this approach requires further validation, it might provide a means for the effective application of therapy for glioblastoma.
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Methods
Patient selection. We collected a series of adult patients with GBM (treated with pembrolizumab or nivolumab on recurrence) from two institutions: Northwestern University (n = 20) and Columbia University (n = 46) with proper IRB approval at each institution. Informed consent was obtained from all patients, and this study complied with all relevant ethical regulations. All patients were treated with the standard therapy of temozolomide and radiation 41 before the administration of PD-1 inhibitors. We excluded patients for whom there were no pre-immunotherapy specimens (either at diagnosis or after standard therapy recurrence) available. The baseline patient characteristics for our cohort are found in Supplementary Table 1 , and the distribution of available data modalities across the cohort is found in Extended Data Fig. 1 .
Sequencing and mapping.
On average, 100-fold exome-wide target coverage was achieved for all of the sequenced tumor samples, and 60-fold for matched blood normal samples was achieved. High-quality reads for these samples were mapped by BWA 42 to the hg19 human genome assembly with default parameters. All mapped reads were then marked for duplicates by Picard to eliminate potential duplications.
Somatic mutations.
To identify somatic mutations from whole-exome sequencing data for samples from patients with GBM, we applied the variant-calling software SAVI2 (statistical algorithm for variant frequency identification 43 ), which is based on an empirical Bayesian method. Specifically, we first generated a list of variant candidates by successively eliminating positions without variant reads, positions with low sequencing depth, positions that were biased for one strand, and positions that contained only low-quality reads. Then, the numbers of high-quality reads for forward-strand reference alleles, reverse-strand reference alleles, forward-strand non-reference alleles, and reverse-stand non-reference alleles were calculated at the remaining candidate positions to build the prior and the posterior distribution of the mutation allele fraction. Finally, somatic mutations were identified on the basis of the posterior distribution of differences in the mutation allele fraction between normal and tumor samples. SAVI2 was able to assess mutations by simultaneously considering multiple tumor samples, as well as their corresponding RNA samples, if available. Only variants with a mutant allele frequency of 5% or greater were included for further analysis.
Analysis of mutation frequencies. Our pipeline is capable of detecting intragenic exon deletions, whereas these alterations are not reported in TCGA. When comparing the rate of PTEN mutations between our cohort and TCGA, for the sake of egalitarianism, we have excluded the three calls of these intragenic exon deletions from our cohort.
Analysis of copy number changes. CNVkit 44 was used to detect copy number changes from whole-exome sequencing data.
Tumor purity estimation. In our cohort, we calculated tumor purity with ABSOLUTE 45 . For TCGA, pre-computed values from ESTIMATE 46 were used.
Gene fusion detection. ChimeraScan 47 was used to generate the starting set of gene fusion candidates. To reduce the false positive rate and nominate potential driver events, we applied the Pegasus annotation and prediction pipeline. We reconstructed the entire fusion sequence on the basis of breakpoint coordinates and assigned a driver score to each candidate fusion via a machine learning model trained largely on GBM data 48 .
Gene expression analysis. Paired-end transcriptome reads were processed using STAR 49 aligner on the basis of the Ensembl GRCh37 human genome assembly with default parameters. Normalized gene expression values were calculated by featureCounts 50 as RPKM. ssGSEA was performed using the R package GSVA 51 . We compared the transcriptomic profiles of the two tumor groups using ssGSEA on the basis of five collections of annotated gene sets from the Molecular Signature Database v6.0 (C2 curated gene sets, C4 computational gene sets, C6 oncogenic gene sets, and C7 immunologic gene sets) 52 . Then, differentially enriched gene sets between the responders and non-responders were defined by an effect size of GSVA score differences being greater than 0.8 and a t-test P value of less than 0.01.
HLA typing and neoantigen prediction.
To test if HLA zygosity affects immunotherapy response or survival, we determined HLA genotypes of 17 patients for whom we had normal blood whole-exome sequencing data and verified using tumor RNA. HLA typing for each sample was performed on blood DNA using the POLYSOLVER algorithm 53 . We furthermore validated the calls with tumor RNA, which achieved perfect concordance on samples where both were available. We used the pVAC-Seq 54 pipeline with the NetMHCcons 55 binding strength predictor to identify neoantigens. NetMHCcons integrates three state-of-the-art methods, NetMHC, NetMHCpan, and PickPocket, to give the most accurate predictions with consideration of the patient's HLA type. As required, we used the variant effect predictor from Ensembl to annotate variants for downstream processing by pVACSeq. For each single-residue missense alteration, major histocompatibility complex binding affinity was predicted for all the wild type and mutant peptides of 8, 9, 10, and 11 amino acids in length. The mutant peptide with the strongest binding affinity was kept for further analysis.
Single-cell data analysis. Single-cell transcriptional profiles were obtained from 9,000 cells over three samples 24 . GSEA was used to assess enrichment of transcriptomic signatures among the samples. Topological representations of cellular expression were constructed with Mapper (Ayasdi Inc.), outputting a network where nodes represent sets of cells with similar characteristics. RGB values were computed for each node in proportion to its composition of Ki-67 + tumor cells, microglia, and CD44 + tumor cells, respectively.
Tumor purity estimation and cellular fraction. ABSOLUTE was used to infer tumor purity and ploidy for each whole-exome sequencing sample by integrating mutational allele frequencies and copy number calls.
Lymphocyte clonality analysis. TCR and immunoglobulin RNA sequences were processed via MiXCR 56 . This was performed for a total of seven patients for whom we had pre-and post-immunotherapy RNA-seq data of sufficient quality. Of these patients (two non-responders and five responders), one from each response criteria had two samples post-therapy (patients 53 and 101). Clonal diversity was calculated through Shannon entropy.
Quantitative multiplex immunofluorescence (qmIF) analysis. FFPE tumor samples were collected for each sample, and H&E slides were reviewed by a neuropathologist (P.C.) to confirm presence of tumor. Opal multiplex staining was performed on FFPE immunoblank slides for CD3 (T cells), CD8 (cytotoxic T lymphocytes), CD68 (microglia/macrophages), HLA-DR (activation marker), PD-L1 (immunosuppression marker), and SOX2 (tumor marker) 45, 46 . Images were acquired using Vectra (PerkinElmer) for whole-slide scanning, and multispectral images were acquired for all areas with at least 99% tissue, using inForm software (PerkinElmer) to unmix and remove autofluorescence. Multispectral images were analyzed using inForm software and R to evaluate density of immune phenotypes within the tumor microenvironment.
Spatial analysis. Phenotyped immunofluorescence data were processed into pair correlation functions (PCFs) using the spatstat R package 57 . Inhomogeneous PCFs were calculated up to a radius of 50 μm for tumor and CD68
+ cells, provided that there were a minimum of 20 cells of that type in the sample. The isotropic edge correction and a normalization power of 2 were used. The area under the curve for each PCF was used as a summary statistic for quantifying clustering, and plots represent the point-wise median PCF across samples with 95% confidence intervals obtained via bootstrapping.
Statistical analysis.
All statistical analyses were conducted in R and Python. In all boxplots, the center lines represent the median, lower and upper box limits are, respectively, the first and third quartiles, and whiskers represent the maximal values up to 1.5 times the interquartile range. All values extending beyond this range are considered fliers/outliers. Violin plots use the Gaussian kernel to estimate densities. The two-sided Wilcoxon rank-sum (Mann-Whitney) test was generally used to compare two populations nonparametrically, unless we had prior knowledge that distributions were normal, in which case the two-sided t-test was used. The P values were adjusted for multiple comparisons using the BenjaminiHochberg (FDR) procedure, and statistical significance was assessed at an adjusted P value threshold of 0.05. 
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